The US FDA's Center for Drug Evaluation and Research (CDER) approved its third novel product of the year with a Feb. 13 blessing for Novartis AG's Egaten (triclabendazole), which also resulted in a priority review voucher for the Swiss drug giant. (See sidebar for related story.)
But the weak start for approvals this year continued to drag on, as the agency also issued its third complete...








